Located in Brittany, France, our industrial site covers more than 64,000 m², entirely dedicated to the innovation and development, production and quality control of pharmaceutical-grade biopolymers. From fermentation, extraction to purification, every step is rigorously controlled by experienced and passionate teams using cutting-edge technologies and processes.
To date, our site operates four independent production units:
To sustainably support the growth of our partners, we are expanding our site with:
“Our industrial strategy is based on long-term reliability. Each investment is driven by a clear ambition: to provide our partners with optimal conditions to grow confidently, relying on the highest standards of pharmaceutical quality and supply security. Thanks to our two independent production units for hyaluronic acid and Polynucelotides, our production capacity is designed to achieve excellence while guaranteeing our customers’ peace of mind in a constantly evolving health and beauty sector. »
Cyril Picault, Chief Operating Officer at HTL Biotechnology
HTL Biotechnology’s mission goes beyond supplying biopolymers. We act as a true catalyst for innovation in medicine and biotechnology.
Thanks to our industrial infrastructure and long-standing expertise in pharmaceutical biopolymers, we empower health and beauty companies worldwide to bring their ambitions to life.
From ophthalmology to aesthetics, and from rheumatology to regenerative medicine, our biopolymers are designed and manufactured according to the highest standards, to support safe, reliable, and sustainable innovation that benefits patients across the globe.
